Indeed, two potentially groundbreaking clinical research trials are underway or soon to be. One, which opened in late April, could change the way breast cancer in sub-Saharan Africa is diagnosed and treated. It could lead also to a better understanding of why the disease tends to strike younger women and to be more aggressive in both sub-Saharan Africa and among African-Americans.
The study is being led by Fred Hutch oncologist-researcher Dr. Manoj Menon along with Orem. Dr. Nixon Niyonzima, a Ugandan physician who in 2016 received his doctorate in molecular and cellular biology from Fred Hutch and the University of Washington, will be involved in running the trial in Kampala.
Still in the planning stages with the goal of opening by early next year, a second clinical trial will study the use of rituximab, a monoclonal antibody treatment commonly used in the United States for patients with aggressive B-cell lymphomas. The medication will be given subcutaneously, or under the skin, which would be easier to deliver in low-resource settings than an intravenous infusion. That study will be led by Global Oncology Deputy Director Dr. Thomas Uldrick with Orem and UCI physician-researcher Dr. Henry Ddungu, who trained in Seattle in 2011.
With a treatment that is more intensive will come the need for better supportive care, including management of infections. That will be the focus of another Seattle trainee, Dr. Margaret “Maggie” Lubwama.
The rituximab study is designed to test the treatment in adults first and then in adolescents and children. Researchers hope it may improve survival for Burkitt lymphoma, a leading cancer killer of children in sub-Saharan Africa. Intensive case management and nutritional supplementation — practices originally provided by the alliance’s Burkitt Lymphoma Project and now taken over by the UCI — boosted survival rates some, but nowhere near as high as in patients treated in the United States. One difference: In Uganda, chemotherapy used to treat the cancer has not changed in 50 years.
“We’re hoping rituximab will be a game-changer,” Warren said.
Training the next generation of leaders
Its 10-year investment in capacity-building — meaning the new building but especially the people trained — has helped the alliance reach this point, according to Dr. Warren Phipps, alliance medical director and director of faculty development in Kampala.
“Early on, you’re building critical mass,” he said. “It just takes time to do that. But once you hit that, things really take off. We’re at that inflection point now.”
That doesn’t mean the alliance has slowed its training efforts. In May, Fred Hutch Global Oncology, in partnership with the UW School of Medicine, the UCI, the government of Uganda, Makerere University, and Mulago Hospital in Kampala, announced the launch of the East Africa Adult Hematology-Oncology Fellowship Program. After a decade of bringing Ugandan physicians to Seattle for training, this new program will send Fred Hutch and UW Medicine oncologists to the UCI.